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Abstract
Objective—The anti-oxidant and proangiogenic protein haptoglobin (Hp) is believed to be 
important for implantation and pregnancy, although its specific role is not known. The three 
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phenotypes (1-1, 2-1 and 2-2) differ in structure and function. Hp 2-2 is associated with increased 
vascular stiffness in other populations. We examined whether Hp phenotype is associated with 
abnormal uterine artery Doppler (UAD) in pregnancy.
Methods—We conducted a secondary analysis of a preeclampsia prediction cohort nested within 
a larger placebo-controlled randomized clinical trial of antioxidants for prevention of 
preeclampsia. We determined Hp phenotype in 2,184 women who completed UAD assessments at 
17 weeks gestation. Women with notching were re-evaluated for persistent notching at 24 weeks 
gestation. Logistic regression was used to assess differences in UAD indices between phenotype 
groups.
Results—Hp phenotype did not significantly influence the odds of having any notch (p=0.32), 
bilateral notches (p=0.72), or a resistance index (p = 0.28) or pulsatility index (p = 0.67) above the 
90th percentile at 17 weeks gestation. Hp phenotype also did not influence the odds of persistent 
notching at 24 weeks (p=0.25).
Conclusions—Hp phenotype is not associated with abnormal UAD at 17 weeks gestation or 
with persistent notching at 24 weeks.
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Introduction
Uterine artery Doppler velocimetry (UAD) is a vascular screening test that identifies 
pregnant women with an increased risk for maternal-placental syndromes, including 
preeclampsia, intrauterine growth restriction and preterm birth [1]. Abnormal UAD is 
typically defined as a notch in the uterine artery velocity waveform at the beginning of 
diastole, or by a resistance or pulsatility index that exceeds the 90th percentile for gestational 
age [2–4]. These abnormalities suggest high resistance and reduced elasticity and 
compliance in the uterine vasculature [5]. Failed systemic vascular adaptation to pregnancy 
[5], maternal cardiac defects [4] and failed dilatory remodeling of the spiral arteries that 
supply the placenta [6–8] may contribute to abnormal UAD.
Haptoglobin (Hp) is a powerful anti-oxidant [9] and pro-angiogenic [10] protein that is 
believed to be important for implantation and pregnancy, although its specific role is not 
known [11, 12]. Hp sequesters iron by binding free hemoglobin following hemolysis [9]. 
Certain phenotypes may also effect vascular stiffness [13, 14] and modulate natural killer 
cell invasiveness [12, 15]. The three Hp genotypes give rise to three distinct phenotypes (Hp 
1-1, 2-1 and 2-2; Figure 1S), which differ in size, structure, and function [9]. Hp 2-2 is the 
weakest anti-oxidant [9]. Hp 2-2 is also associated with increased systemic vascular 
resistance [14], reduced large and small artery elasticity [14], and increased pulse wave 
velocity in individuals with Type 2 diabetes [13]. This may contribute to the two-fold 
increase in cardiovascular event risk in Hp 2-2 diabetics, compared to Hp 1-1 and 2-1 
diabetics [16].
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Small case-control studies suggest that Hp phenotype may predict adverse pregnancy 
outcomes, including preeclampsia [17, 18], gestational diabetes [19], and premature rupture 
of membranes [20]. However, we were unable to confirm a relationship between Hp 
phenotype and preeclampsia risk in large cohorts of low-risk nulliparous women [21] or 
women with Type 1 diabetes [22] participating in randomized controlled trials of 
antioxidants for preeclampsia prevention. This highlights the importance of using large 
cohort studies when examining Hp phenotype and pregnancy outcome to reduce the 
likelihood of spurious findings [23].
The potential effects of Hp phenotype on abnormal UAD have not been investigated. Hp 2-2 
is associated with increased vascular stiffness in Type 2 diabetes [13, 14], however little is 
known about Hp phenotype and vascular stiffness in other populations. We conducted a pre-
planned secondary analysis to determine whether Hp phenotype was associated with 
abnormal UAD in the trial of low risk nulliparous women [21]. We hypothesized that Hp 
2-2 women would be more likely to have abnormal UAD at 17 weeks gestation and 
persistent notching at 24 weeks gestation. We tested this hypothesis in a preeclampsia 




We conducted a secondary analysis of a double-blind, multicenter randomized controlled 
trial in which nulliparous, low risk women received daily doses of 400 IU of vitamin E and 
1000 mg of vitamin C, or placebo, from 9–16 weeks gestation until delivery (NCT 
00135707) [24]. The trial was conducted between 2003 and 2008 by 16 centers in the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development 
Maternal-Fetal Medicine Units Network. A subset of 2,434 women who started treatment/
placebo by 9–12 weeks gestation were enrolled in a nested preeclampsia prediction cohort 
(women not in the prediction cohort could start treatment/placebo as late as 16 weeks 
gestation). Women in the prediction cohort provided extra blood samples at each time point 
and underwent UAD assessment at 17 weeks gestation. All subjects provided written, 
informed consent before participating. Hp phenotyping was performed at the University of 
Pittsburgh (Institutional Review Board approval PRO10010368).
UAD
UAD was performed in women enrolled in the prediction study at approximately 17 weeks 
gestation. If a notch was present on any waveform, a second ultrasound was scheduled at 24 
weeks gestation to identify women with persistent notches. Sonographers completed a 
certification exam to ensure that procedures were standardized across centers. Doppler 
examinations were performed transabdominally. If the sonographer could not obtain an 
adequate transabdominal image, transvaginal Doppler was performed. Three waveforms 
from the right and left uterine arteries were recorded. The uterine artery was insonated as it 
entered the uterus, one cm distal to where it crossed the external iliac artery. The resistance 
index (RI) was calculated as (systolic velocity – diastolic velocity) / systolic velocity. The 
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pulsatility index (PI) was calculated as (systolic velocity – diastolic velocity) / [(systolic 
velocity + diastolic velocity) / 2]. The RI and PI of the right and left uterine arteries were 
averaged. A notch was defined as a clear increase in velocity at the beginning of diastole. 
UAD indices were calculated at each study site by a sonographer who had completed the 
study certification exam. Multiples of the median for the RI and PI were calculated as 
described previously [8]. Expected medians were calculated based on a subject’s gestational 
age, maternal weight and race. A RI or PI greater than the 90th percentile for gestational age 
was considered abnormal.
Hp Phenotyping
Phenotyping was performed as described previously [18] by individuals who were blinded 
to patient data. 5 µl serum samples supplemented with human hemoglobin (Sigma-Aldrich, 
St. Louis, MO) were run on 6% tris-glycine native gels (Invitrogen, Carlsbad, CA). Proteins 
were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA).
Hemolyzed samples and samples with low Hp concentrations were phenotyped by sodium 
dodecyl sulfate polyacrilamide gel electrophoresis (SDS PAGE) of 1 to 6 µl of serum. 
Samples were run on 12% tris-glycine gels (Invitrogen, Carlsbad, CA) and transferred to 
PVDF. PVDF was incubated with blocking solution (tris-buffered saline containing 5% non-
fat milk, 0.1% Tween 20), and primary (1:5,000, Polyclonal Rabbit Anti-Human 
Haptogloin, DakoCytomation, Carpinteria, CA) and secondary (1:25,000, Goat anti-Rabbit 
IgG horseradish peroxidase, Millipore) antibodies. Incubations were performed at room 
temperature for one hour each.
PVDF was stained for peroxidase activity (SuperSignal West Pico Chemiluminescent 
Substrate, Fisher Scientific, Pittsburgh, PA) and imaged (FlouroChem Q System, Cell 
Biosciences, Santa Clara, CA). Hp phenotypes were identified by banding patterns of the 
Hp-hemoglobin complexes (Figure 1S, native PAGE) or the Hp α1 and α2 alleles (SDS 
PAGE).
Statistical Analysis
Baseline characteristics across phenotypes were compared using the Chi-square test for 
categorical variables and the Kruskal-Wallis test for continuous variables. Logistic models 
were used to assess the odds of abnormal UAD at the first Doppler exam and persistent 
notching at the second exam. All models were adjusted for age, gestational age at Doppler 
exam, treatment group, characteristics that differed between Hp phenotype groups (age, 
race, education, and prenatal/multivitamin use at randomization), and BMI, which was 
associated with UAD indices.
Results
Subjects
The prediction cohort included 2,434 women. We excluded 250 women because pregnancy 
outcome data were not available (n = 40), the UAD exam was not completed by 21 weeks 
gestation (n = 206), blood samples were not available (n = 1), or Hp was undetectable (Hp 0, 
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n = 3). Of the remaining 2,184 women, 49 had the rare 2-1M phenotype. Hp 2-1M 
individuals produce large amounts of Hp 1-1 and only small amounts of the Hp 2-1 isoforms 
due to a modification of the α2 allele (Figure 1S) [9]. The opposite banding pattern is 
observed in Hp 2-1 individuals, who produce very little Hp 1-1 and large amounts of the Hp 
2-1 isoforms. Hp 2-1M women were excluded from statistical analyses of UAD indices due 
to small sample size. 1,066 women were randomized to receive daily vitamin C and E 
supplementation. This included 53% of Hp 1-1 women (n = 238), 48% of Hp 2-1 women (n 
= 488), and 51% of Hp 2-2 women (n = 340). The remaining 1,069 women were 
randomized to receive placebo.
Phenotype prevalence differed by race (Table 1), and was similar to published values for 
white, black and Hispanic North Americans [25]. Age increased progressively across the Hp 
2-1M, 1-1, 2-1 and 2-2 groups (Table 1). Hp 2-2 women were older and more educated than 
women with the other phenotypes, and were more likely to report vitamin use at 
randomization than women with the Hp 1-1 and 2-1 phenotypes. The phenotype groups did 
not differ with respect to pre-pregnancy BMI, blood pressure at randomization, smoking, 
history of a previous pregnancy ending prior to 20 weeks, or family history of preeclampsia. 
Hp 2-2 women were randomized slightly later than Hp 1-1 women, and completed their first 
UAD assessment slightly earlier than Hp 1-1 and 2-1 women. Although statistically 
significant, these 1–3 day differences are unlikely to have had any clinical impact.
Subsequent analyses of UAD indices were adjusted for characteristics that differed between 
the 1-1, 2-1 and 2-2 groups (race, age, education, and vitamin use). The “White” and 
“Other” groups were pooled for race adjustments, as the phenotype prevalence in the 
“Other” group was most similar to whites. There were no interactions between Hp 
phenotype and race for UAD indices. Treatment group (vitamins vs. placebo) did not 
significantly affect any of the UAD indices examined; therefore treatment groups were 
pooled for all analyses. Results were not different in when the placebo group (211 Hp 1-1 
women, 537 Hp 2-1 women, and 321 Hp 2-2 women) was analyzed alone.
Relationship Between Hp Phenotype and UAD Indices at 17 Weeks Gestation
334 women (15.5%) had notching at 17 weeks gestation. Hp phenotype did not significantly 
influence the odds of having any notch or bilateral notching (Table 2) after adjusting for age, 
gestational age at Doppler exam, race, education, vitamin use, body weight and treatment 
group. The odds of having a RI and PI above the 90th percentile for gestational age did not 
differ between women of different Hp phenotypes.
Relationship Between Hp Phenotype and Persistent Notching at 24 Weeks Gestation
268 of the 334 women (80.2%) who had notching at 17 weeks gestation returned for a 
second UAD assessment at 24 weeks gestation (Table 3). Six women with the 2-1M 
phenotype were excluded. The percentage of women who did not return was not different 
between Hp phenotype groups (data not shown). Gestational age at the second UAD exam 
did not differ between the phenotype groups. 84 women (32.1%) who completed the second 
UAD exam had persistent notching (any notch or bilateral notch). The odds of persistent 
notching did not differ significantly between women with the Hp 1-1, 2-1 and 2-2 
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phenotypes (p=0.25). Only 22 women (8.2%) had persistent bilateral notches. Statistical 
analyses were not performed due to small sample size.
Discussion
In contrast to our hypothesis, we found that Hp phenotype was not associated with the 
prevalence of any notch or bilateral notches, or the odds of having a RI or PI above the 90th 
percentile for gestational age, at 17 weeks gestation. There was also no relationship between 
Hp phenotype and persistent notching at 24 weeks gestation. This study extends the existing 
literature regarding Hp phenotype and pregnancy to include UAD. The large sample size, 
cohort design, and racial and ethnic diversity of the cohort (50% non-Hispanic white, 25% 
Hispanic, 23% non-Hispanic black) are significant strengths.
Although Hp is believed to be important for implantation and pregnancy, it’s functional role 
is not known [11]. Increases in Hp concentration in the rabbit oviduct and uterus follow the 
time-course of blastocyst transit, and the blastocyst incorporates maternal Hp into its extra-
embryonic matrix [11]. Phenotype effects cannot be examined in the rabbit, as this species 
only has the Hp 1-1 phenotype [26]. In humans, Hp concentrations in the uterine 
endometrium increase from the follicular to the luteal phase of the menstrual cycle [27]. The 
uterine decidua has high Hp concentrations at term [27]. Although Hp concentration 
depends on phenotype [28], this study did not examine the potential effects of phenotype 
[27]. Mechanistic studies examining the functional significance of these increases in Hp 
concentration are needed.
There are several possible explanations for the absence of a relationship between Hp 
phenotype and UAD indices. One possibility is that the phenotype-dependent differences in 
Hp’s functions do not have clinically significant effects on the processes that affect UAD 
during pregnancy. Alternatively, the strengths and weaknesses of the phenotypes may offset 
one another (i.e. the superior antioxidant capacity of Hp 1-1 may be counterbalanced by the 
vascular and proangiogenic properties of Hp 2-2), such that the overall effect of Hp 
phenotype is not clinically significant. A third possibility is that the multi-factorial nature of 
abnormal UAD may obscure any potential effect of Hp phenotype on the individual 
pathological mechanisms that contribute to abnormal UAD (failed systemic vascular 
adaptation, deficient spiral artery remodeling and placentation, and/or cardiac defects). This 
might occur if Hp phenotype only alters the risk of one type of pathology, or if different Hp 
phenotypes are associated with different pathologies. In this case, tests specific to each 
individual mechanism (peripheral vascular function testing, placental bed biopsies and 
echocardiography) would be necessary to detect a potential effect of Hp phenotype. These 
expensive and time consuming measurements were not feasible in this large cohort.
Most research examining the relationship between Hp phenotype and adverse pregnancy 
outcomes focuses on preeclampsia [17, 18, 29, 30]. The largest case-control studies 
suggested that Hp 1-1 was associated with a lower preeclampsia risk compared to Hp 2-1 
[18], or Hp 2-1 and 2-2 [17]. However, we found no relationship between Hp phenotype and 
preeclampsia risk in 4,500 women from the present trial, suggesting that the results of small 
case-control studies may have been spurious findings [21]. This highlights the need for 
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large, prospective studies [21, 23]. Two small case-control studies examined the potential 
impact of Hp phenotype on other adverse pregnancy outcomes [19, 20]. Austrian women 
with gestational diabetes were more likely to have the Hp α2 allele than women with 
uncomplicated pregnancies [19]. In contrast, Korean women with premature rupture of 
membranes were more likely to have the Hp 1-1 phenotype (23% vs. 8%) than women with 
uncomplicated pregnancies [20]. The preeclampsia data suggest that these findings should 
be verified in large cohorts. The prediction cohort included too few women with gestational 
diabetes (n = 83) to examine this outcome. Premature rupture of membranes (n = 287) will 
be examined in a future study.
Limitations
This study has two important limitations. A notch was defined as a clear increase in velocity 
at the beginning of diastole, rather than by measured criteria. However, all sonographers 
completed a certification exam to ensure that waveforms were read consistently across sites. 
Second, UAD was assessed at approximately 17 weeks gestation, and results may differ at 
other gestational ages. This gestational age was selected for the original study because 
several large prospective studies reported that abnormal UAD in the second trimester or late 
first trimester was useful in predicting preeclampsia [1]. Early reports also suggested that Hp 
phenotype was associated with preeclampsia risk [17, 18]; hence we sought to examine the 
potential effects of Hp phenotype on UAD both as a vascular test, and as a potential 
mechanism leading to increased preeclampsia risk. However, subsequent analyses 
demonstrated that abnormal UAD had poor sensitivity for predicting preeclampsia in this 
cohort [8], and we were also unable to confirm a relationship between Hp phenotype and 
preeclampsia risk [21].
In conclusion, Hp phenotype did not identify women at increased risk of abnormal UAD in a 
racially diverse pregnancy cohort of low risk, nulliparous women. Large cohorts are needed 
to confirm the results of small case-control studies suggesting that Hp phenotype 
significantly affects the risk of gestational diabetes [19] and premature rupture membranes 
[20]. Mechanistic studies are also needed to identify the specific role of Hp in implantation 
and pregnancy, and to examine the potential role of Hp phenotype.
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J. Grant, M. Wallace, K. Bailey
Columbia University, New York, NY – S. Bousleiman, R. Alcon, K. Saravia, F. Loffredo, 
A. Bayless (Christiana), C. Perez (St. Peter's University Hospital), M. Lake (St. Peter's 
University Hospital), M. Talucci
University of North Carolina at Chapel Hill, Chapel Hill, NC – K. Boggess, K. Dorman, J. 
Mitchell, K. Clark, S. Timlin
Case Western Reserve University-MetroHealth Medical Center, Cleveland, OH – J. Bailit, 
C. Milluzzi, W. Dalton, C. Brezine, D. Bazzo
University of Texas Southwestern Medical Center, Dallas, TX – K. Leveno, J. Sheffield, L. 
Moseley, M. Santillan, K. Buentipo, J. Price, L. S. Hermann, C. Melton, Y. Gloria-
McCutchen, B. Espino
Northwestern University, Chicago, IL – M. Dinsmoor (NorthShore University 
HealthSystem), T. Matson-Manning, G. Mallett
University of Texas Health Science Center at Houston-Children’s Memorial Hermann 
Hospital, Houston, TX – S. Blackwell, K. Cannon, S. Lege-Humbert, Z. Spears
Brown University, Providence, RI – M. Carpenter, J. Tillinghast, M. Seebeck
The Ohio State University, Columbus, OH – J. Iams, F. Johnson, S. Fyffe, C. Latimer, S. 
Frantz, S. Wylie
Drexel University, Philadelphia, PA – M. Talucci, M. Hoffman (Christiana), J. Benson 
(Christiana), Z. Reid, C. Tocci
Wake Forest University Health Sciences, Winston-Salem, NC – P. Meis, M. Swain
Oregon Health & Science University, Portland, OR – J. Tolosa, W. Smith, L. Davis, E. 
Lairson, S. Butcher, S.
Maxwell, D. Fisher
University of Texas Medical Branch, Galveston, TX – J. Moss, B. Stratton, G. Hankins, J. 
Brandon, C. Nelson-Becker, G. Olson, L. Pacheco
Wayne State University, Detroit, MI – G. Norman, S. Blackwell, P. Lockhart, D. Driscoll, 
M. Dombrowski
The George Washington University Biostatistics Center, Washington, DC – E. Thom, R. 
Clifton, T. Boekhoudt, L. Leuchtenburg
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National Heart, Lung, and Blood Institute, Bethesda, MD – V. Pemberton, J. Cutler, W. 
Barouch
Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
Bethesda, MD – C. Spong, S. Tolivaisa
MFMU Steering Committee Chair (University of Texas Medical Center, Galveston, TX) – 
G.D. Anderson, M.D.
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Table 3







Gestational age at 1st UAD assessment 16.9 ± 1.0 16.6 ± 1.1 16.6 ± 0.92
Gestational age at 2nd UAD assessment 24.2 ± 1.0 24.3 ± 0.9 24.1 ± 0.9
Persistent notches (any notch or bilateral notches) n (%) 17 (32.1%) 49 (36.6%) 18 (24.0%)
OR (95% CI)* 1.16 (0.50, 2.66) 1.68 (0.87, 3.26) 1
Values are mean ± standard deviation unless otherwise indicated. Abbreviations: OR, odds ratio; CI, confidence interval. 268 women with notches 
at the first assessment returned for a 2nd UAD assessment. Six women with the Hp 2-1M phenotype were excluded.
a
Adjusted for age, gestational age at Doppler exam, race, education, vitamin use, pre-pregnancy BMI and treatment group.
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